Baiji Shenzhou: Signs Cooperation Agreement with Hua Hui An Jian

Baiji Shenzhou announced that its wholly-owned subsidiary, Guangzhou Baiji Shenzhou Biopharmaceutical Co., Ltd., has signed an "Exclusive Option, License and Collaboration Agreement" with Huahui Anjian Biotechnology Co., Ltd. According to the agreement, Huahui Anjian has agreed to grant Baiji Shenzhou Guangzhou an exclusive option to obtain an exclusive license to develop, manufacture, and commercialize three specific compounds targeting PD-1, CTLA-4, and VEGF-A that are under development by Huahui Anjian globally, as well as any products containing such compounds. Baiji Shenzhou Guangzhou will pay Huahui Anjian an upfront payment of 20 million US dollars, and if Baiji Shenzhou Guangzhou exercises the option within the specified period, Huahui Anjian will be entitled to an additional 100 million US dollars in exercise payment. After achieving development and regulatory milestones, Huahui Anjian will be entitled to receive up to a maximum of 374 million US dollars in payments; after achieving sales milestones, Huahui Anjian will be entitled to receive up to a maximum of 1.53 billion US dollars in payments; and Huahui Anjian also has the right to receive tiered royalties.